At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago (May 29 – June 2), researchers presented real-world data suggesting GLP-1 receptor agonists may reduce metastatic progression in several obesity-related cancers. The findings add to a growing body of evidence that these medications do more than help with weight loss.
What the Research Found
A real-world analysis of 12,112 patients compared outcomes between those taking GLP-1 receptor agonists and those taking DPP-4 inhibitors (gliptins). The study examined seven obesity-related cancers: breast, prostate, non-small cell lung cancer, colorectal, liver, kidney, and pancreatic adenocarcinoma.
The results showed that GLP-1 users were significantly less likely to progress to metastatic disease in four cancer types: lung, breast, colorectal, and liver. Additionally, GLP-1 receptor expression was associated with overall survival, suggesting GLP-1 signaling may play a direct role in cancer biology.
A Separate Study on Breast Cancer
In a parallel analysis of more than 100,000 women who were overweight and eligible for mammogram screening, University of Pennsylvania researchers found that those taking GLP-1 medications were less likely to develop breast cancer compared to non-users. This represents one of the largest real-world datasets examining GLP-1s and cancer prevention.
Important context: These are observational studies, not randomized controlled trials. They show associations, not definitive cause-and-effect. The researchers themselves have called for randomized controlled trials to establish stronger evidence. Do not take GLP-1 medications for cancer prevention — they are not approved for this use.
Why This Matters for GLP-1 Patients
If you're already taking or considering GLP-1 medication for weight loss, this research provides additional context for your decision. The weight loss itself likely contributes to reduced cancer risk — obesity is a known risk factor for multiple cancers. Whether GLP-1 medications provide cancer-protective effects independent of weight loss is the question researchers are now trying to answer.
Providers Worth Comparing
If you're evaluating GLP-1 options, here are providers with strong clinical support and transparent pricing.
Sunlight $159/mo sema, $239/mo tirz · LegitScript certified. Flat pricing — $159 first month, $179 ongoing (semaglutide). No membership, free shipping, HSA/FSA.
⚕️ Compounded medications are not FDA-approved. They are prepared by licensed pharmacies under physician supervision.
Embody From $149/mo · Injectable semaglutide with coaching included. LegitScript-certified 503B pharmacy sourcing. Strong onboarding support.
⚕️ Compounded medications are not FDA-approved. They are prepared by licensed pharmacies under physician supervision.
⚕️ Compounded medications are not FDA-approved. They are prepared by licensed pharmacies under physician supervision.